UroGen Pharma Ltd. (NASDAQ:URGN) filed its annual report (Form 10-K) with the Securities and Exchange Commission on March 02, 2026.
The Healthcare company reported annual revenue of and net income of for fiscal year 0.
UroGen Pharma Ltd.'s stock currently trades at $21.70 with a market capitalization of $1.0B.
The 10-K is the most comprehensive annual report a public company files, containing detailed financial statements, management discussion and analysis (MD&A), risk factors, and business segment breakdowns. For UroGen Pharma Ltd. investors, the 10-K provides depth that quarterly reports don't — including full-year trends, long-term debt schedules, and off-balance-sheet items.
Key sections to review: MD&A for management's narrative on performance, risk factors for newly disclosed threats, and the notes to financial statements for accounting changes that could affect reported earnings.
All SEC filings for UroGen Pharma Ltd. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
